in-PharmaTechnologist.com presents its round-up of the latest pharmaceutical industry appointments, including news from Okairos, Immunovaccine, and SteadyMed.
Non-profit epilepsy research sponsor, Epilepsy Therapy Project (ETP), has announced it is to invest in central nervous system (CNS) drug delivery specialist, ICVrx, to support the development of novel drug tech designed to tackle refractory epilepsy.
Outsourcing-Pharma reviews the latest developments in drug delivery with news from HepaLife Technologies and Jeiven, SurModics and Edge, as well as EDAP, Epitarget AS and INSERM.
Encap has announced its DuoCap capsule delivery system has been granted US and European patents that strengthen the firm’s portfolio in the delivery of pharmaceutical active agents that require controlled release.
Aphios has been awarded a patent that details an improved process to formulate a polymer-based drug delivery nanotechnology platform. The method offers a more sustainable, consistent administration of therapeutics with less dosage-dependent side effects.
Researchers believe they have found a way of transforming a key element of liquid crystal display (LCD) televisions into a substance that can be used in pills and dressings designed to deliver drugs to certain parts of the body.
New research could make it possible for scientists to use silicon particles as an effective drug delivery system that enables fragile small interfering RNA (siRNA) based drugs to be directly transported to the disease’s location.
Crospon has spun out its transdermal controlled release patch into a distinct company, two years after it licensed the system from HP, using funding from a pharma firm to further its development.
3M Drug Delivery Technologies has expanded its respiratory drug delivery system offering with its Taper DPI which, it claims, makes carrier compounds unnecessary and will help drug formulators save millions.
Cambridge Consultants has developed its ‘connected patient’ technology, which creates a communication network between drug delivery devices and healthcare professionals to increase compliance.
SurModics has completed the three year Phase I trial of I-vation TA (triamcinolone acetonide), which uses a novel drug delivery system capable of sustained ocular release of a therapeutic.
OctoPlus has inked a deal with a European biotech that will see it evaluate the feasibility of a controlled release formulation using its proprietary drug delivery technology.
MicroCHIPS scooped the drug delivery technology award at this year’s AAPS, after which CEO John Santini spoke to in-PharmaTechnologist.com about the device and what the future holds for the company.
in-PharmaTechnologist.com presents its latest round up of developments in drug delivery, including Philips first foray into drug delivery and a licensing deal for 3M.
UK-based Melbourn Scientific is now offering an integrated package of formulation, method development, analysis and short-run clinical manufacture services to industrial clients.
DSM Biomedical and Caliber Therapeutics aim to expand their presence in the balloon catheter market with a project to develop new drug delivery devices for vascular diseases, including atherosclerosis.
Brookwood Pharmaceuticals, a subsidiary of SurModics, has acquired the exclusive rights to all pharmaceutical applications of PharmaSol’s nanostructured lipid carrier (NLC) technology.
A comprehensive review of stimuli-responsive molecularly imprinted
polymers (MIPs) in Current Drug Delivery has highlighted
their potential within the pharmaceutical industry.
US demand for drug delivery systems is set to increase by over 10
per cent a year, reaching $132bn in 2012 with growth driven by
injectable biologic dugs, according to a new study by the Freedonia
Group.
Flamel Technologies has yet again experienced a net loss of $37.2m
for 2007, following a string of bad fortune in 2005 and 2006, but
believes it may be about to turn the corner.
Contract pharmaceutical development company Azopharma has carved
out its drug delivery segment into a new company, APIcross Drug
Delivery Technologies.
A new Belgian company has joined the throng of pharmas tapping into
the booming drug delivery business, but claims that its unique
technologies will carve it a place as one of the industry's key
players.
UK firm Protherics has inked a deal with a Korean partner allowing
the company to make use of its temperature sensitive sustained
release drug delivery system.
A combination of new drugs, new patient needs and new technologies
is likely to fuel steady growth in the transdermal/transmucosal
drug delivery market during the years to 2010.
Drug delivery technology firm Apogee has signed an exclusive
licence to get its hands on a microneedle-based drug delivery
technology that it hopes will significantly enhance the company's
PyraDerm intradermal drug delivery system.
Pfizer has homed in pSivida's controlled release drug delivery
technology, signing a research and licensing deal worth $165m
(€123.5m) and focusing keenly on the company's Medidur technology
for new ophthalmic applications.
Novel needle-free injections that don't cause the pain and bruising
common with existing needle-free devices have been developed by a
team in California.
The implantable/injectable drug delivery market generated record
revenues of $9.8bn (€7.4bn) worldwide in 2006 but is set to
continue growing, driven by growing demand for novel drug delivery
technologies.
A Japanese firm announced this week that it has developed a
biodegradable polymer based drug delivery system that could
significantly improve the efficacy of chemotherapy drugs and reduce
drug development costs.
BioProgress are set to speed up commercialisation of NRobe, their
solid oral dose system, following completion of a restructuring
agreement with Magenta Oral Dose Design.
The rapidly growing market for oral drug delivery is forecast to
increase 48 per cent to reach a $52.1 billion in revenues by 2010,
with an annual growth rate of 10 per cent, according to a new study
by Kalorama Information.
A new anti-cancer drug delivery system which allows more targeted
treatment and helps avoid the unsafe and unpleasant side effects of
chemotherapy is due to enter clinical trials in Europe and the US
for use with anti-cancer drug...
Drug delivery company MonoSolRx has announced it has received a
$38m (€29m) funding from an investment group, illustrating the
appeal of the company's dissolving film technology.
Roche has invested $20m in a new technology that has the potential
to dramatically enhance the delivery of subcutaneous drugs by
acting like a 'molecular machete'.
Australia's pSivida said that an undisclosed US firm is now
evaluating its novel BioSilicon technology with the aim of
developing new transdermal drug delivery systems.
In a deal worth up to $19.9m (€15.6m), US drug delivery company
Inyx has acquired contract pharmaceutical packaging firm Pharmapac,
seeking to enhance its secondary-packaging capabilities for a wide
range of dosage forms.
Researchers have discovered a new method for delivering drugs to
the eye using biodegradable polymer nanoparticles that promise
controlled release and better bioavailability than eye drops.
Ferro Pfanstiehl Laboratories has commissioned a new validated
current good manufacturing practice (cGMP) supercritical
fluid-based particle engineering pilot facility, offering sizing,
purification and formulation services to its...
Canadian contract manufacturer Patheon has teamed up with specialty
pharmaceutical firm Depomed to offer its clients a controlled
release formulation which can grant their drugs increased
bioavailability and less frequent dosing.
Drug manufacturers are increasingly turning to specialised
providers of analytical services for the solid state
characterisation of their formulations, seeking answers to
processing issues, drug delivery challenges and even protecting...
Pharmaceutical excipients can have a profound impact on the release
profile of drugs, driving fine chemical companies to raise their
game since they realise their clients see excipients as more than
inactive ingredients.
More and more drugmakers are turning to health care companies not
just for their drug delivery technologies but also for their
regulatory and manufacturing expertise, asking them to take their
product from early stages all the way...